Design and Synthesis of a Series of l-trans-4-Substituted Prolines as Selective Antagonists for the Ionotropic Glutamate Receptors Including Functional and X-ray Crystallographic Studies of New Subtype Selective Kainic Acid Receptor Subtype 1 (GluK1) Antagonist (2S,4R)-4-(2-Carboxyphenoxy)pyrrolidine-2-carboxylic Acid. 2017

Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch

Ionotropic glutamate receptor antagonists are valuable tool compounds for studies of neurological pathways in the central nervous system. On the basis of rational ligand design, a new class of selective antagonists, represented by (2S,4R)-4-(2-carboxyphenoxy)pyrrolidine-2-carboxylic acid (1b), for cloned homomeric kainic acid receptors subtype 1 (GluK1) was attained (Ki = 4 μM). In a functional assay, 1b displayed full antagonist activity with IC50 = 6 ± 2 μM. A crystal structure was obtained of 1b when bound in the ligand binding domain of GluK1. A domain opening of 13-14° was seen compared to the structure with glutamate, consistent with 1b being an antagonist. A structure-activity relationship study showed that the chemical nature of the tethering atom (C, O, or S) linking the pyrrolidine ring and the phenyl ring plays a key role in the receptor selectivity profile and that substituents on the phenyl ring are well accommodated by the GluK1 receptor.

UI MeSH Term Description Entries
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D058468 Receptors, Ionotropic Glutamate A class of ligand-gated ion channel receptors that have specificity for GLUTAMATE. They are distinct from METABOTROPIC GLUTAMATE RECEPTORS which act through a G-protein-coupled mechanism. Ionotropic Glutamate Receptor,Ionotropic Glutamate Receptors,Glutamate Receptor, Ionotropic,Glutamate Receptors, Ionotropic,Receptor, Ionotropic Glutamate
D018092 Receptors, Kainic Acid A class of ionotropic glutamate receptors characterized by their affinity for KAINIC ACID. Kainate Receptors,Kainic Acid Receptors,Receptors, Kainate,Kainate Receptor,Kainic Acid Receptor,Receptor, Kainate,Receptor, Kainic Acid
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
February 2011, ACS chemical neuroscience,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
August 2015, Journal of medicinal chemistry,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
March 2020, ACS chemical neuroscience,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
July 2001, Bioorganic & medicinal chemistry letters,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
September 2002, Bioorganic & medicinal chemistry letters,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
March 2020, ACS chemical neuroscience,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
December 2007, European journal of pharmacology,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
August 1998, Bioorganic & medicinal chemistry letters,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
June 2019, ACS chemical neuroscience,
Niels Krogsgaard-Larsen, and Claudia G Delgar, and Karina Koch, and Patricia M G E Brown, and Charlotte Møller, and Liwei Han, and Tri H V Huynh, and Stinne W Hansen, and Birgitte Nielsen, and Derek Bowie, and Darryl S Pickering, and Jette Sandholm Kastrup, and Karla Frydenvang, and Lennart Bunch
March 2011, ChemMedChem,
Copied contents to your clipboard!